Aclaris Therapeutics Stock Price, News & Analysis (NASDAQ:ACRS) $0.87 0.00 (0.00%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$0.84▼$0.9150-Day Range$0.64▼$6.8552-Week Range$0.59▼$18.54Volume2.61 million shsAverage Volume1.65 million shsMarket Capitalization$61.92 millionP/E RatioN/ADividend YieldN/APrice Target$23.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aclaris Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,548.5% Upside$23.17 Price TargetShort InterestBearish10.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$30,480 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.65) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector324th out of 949 stocksPharmaceutical Preparations Industry134th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.17, Aclaris Therapeutics has a forecasted upside of 2,548.5% from its current price of $0.87.Amount of Analyst CoverageAclaris Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.44% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRS. Previous Next 2.5 News and Social Media Coverage News SentimentAclaris Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aclaris Therapeutics this week, compared to 2 articles on an average week.Search Interest38 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 1,167% compared to the previous 30 days.MarketBeat Follows2 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,480.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Aclaris Therapeutics is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($1.65) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aclaris Therapeutics Stock (NASDAQ:ACRS)Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More ACRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRS Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comDown -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)November 15, 2023 | reuters.comAclaris shares plummet on terminating development of rheumatoid arthritis drugNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 14, 2023 | msn.comCantor Fitzgerald Downgrades Aclaris Therapeutics (ACRS)November 14, 2023 | bizjournals.comAclaris halts work on its experimental rheumatoid arthritis drug after clinical trial failureNovember 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Aclaris TherapeuticsNovember 14, 2023 | finance.yahoo.comAclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis StudyNovember 14, 2023 | msn.comStifel Downgrades Aclaris Therapeutics (ACRS)November 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 13, 2023 | benzinga.comCrude Oil Gains Over 1%; US Budget Deficit Narrows For OctoberNovember 13, 2023 | reuters.comAclaris Therapeutics to stop development of rheumatoid arthritis drugNovember 13, 2023 | markets.businessinsider.comAclaris Therapeutics Says Will Discontinue Further Development Of ATI-450 ProgramNovember 13, 2023 | benzinga.comWhy Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today?November 13, 2023 | finance.yahoo.comAclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNovember 11, 2023 | finance.yahoo.comAnalysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This WeekNovember 9, 2023 | morningstar.comAclaris Therapeutics Inc ACRSNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Aclaris Therapeutics (ACRS) and Guardant Health (GH)November 6, 2023 | finance.yahoo.comAclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comAclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateOctober 5, 2023 | bizjournals.com'Luck and timing': Serial entrepreneur Dr. Neal Walker on what it takes to successfully launch a life sciences companyOctober 4, 2023 | markets.businessinsider.comBuy Rating Affirmed for Aclaris Therapeutics: Promising Developments in Eczema Treatment Trials and Prospective PartnershipsOctober 3, 2023 | finance.yahoo.comAclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)September 20, 2023 | finance.yahoo.comWe Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business GrowthSeptember 20, 2023 | finance.yahoo.comAclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 19, 2023 | markets.businessinsider.comExpert Ratings for Aclaris TherapeuticsSeptember 19, 2023 | markets.businessinsider.comJefferies Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)September 18, 2023 | finance.yahoo.comAclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorSee More Headlines Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$23.17 High Stock Price Target$38.00 Low Stock Price Target$9.00 Potential Upside/Downside+2,548.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,910,000.00 Net Margins-534.83% Pretax Margin-534.83% Return on Equity-64.53% Return on Assets-48.87% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual Sales$29.75 million Price / Sales2.08 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book0.40Miscellaneous Outstanding Shares70,790,000Free Float66,901,000Market Cap$61.92 million OptionableOptionable Beta0.65 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Neal S. Walker D.O. (Age 53)Co-Founder & Chairman Comp: $955.69kDr. Douglas J. Manion Frcp(C) (Age 62)M.D., CEO, President & Director Comp: $572.16kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Comp: $600.02kDr. Gail Cawkwell M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $371.17kMr. Kevin Balthaser (Age 36)Chief Financial Officer Mr. Robert A. Doody Jr.Senior Vice President of Investor RelationsMr. Matthew Rothman J.D.General Counsel & Corporate SecretaryMs. Jill ConwellChief People OfficerMr. Gary A. DeCrescenzoSenior Vice President of Pharmaceutical Research & DevelopmentDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRLeap TherapeuticsNASDAQ:LPTXInflaRxNASDAQ:IFRXAdageneNASDAQ:ADAGTiziana Life SciencesNASDAQ:TLSAView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 932,311 shares on 11/24/2023Ownership: 0.218%Walleye Capital LLCSold 225,318 shares on 11/21/2023Ownership: 0.164%Jacobs Levy Equity Management Inc.Bought 124,132 shares on 11/17/2023Ownership: 0.248%Wolverine Trading LLCSold 11,000 shares on 11/16/2023Ownership: 0.000%GSA Capital Partners LLPSold 45,491 shares on 11/15/2023Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions ACRS Stock Analysis - Frequently Asked Questions Should I buy or sell Aclaris Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACRS shares. View ACRS analyst ratings or view top-rated stocks. What is Aclaris Therapeutics' stock price target for 2024? 8 equities research analysts have issued 12-month price objectives for Aclaris Therapeutics' stock. Their ACRS share price targets range from $9.00 to $38.00. On average, they expect the company's stock price to reach $23.17 in the next twelve months. This suggests a possible upside of 2,548.5% from the stock's current price. View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts. How have ACRS shares performed in 2023? Aclaris Therapeutics' stock was trading at $15.75 at the beginning of 2023. Since then, ACRS stock has decreased by 94.4% and is now trading at $0.8747. View the best growth stocks for 2023 here. Are investors shorting Aclaris Therapeutics? Aclaris Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,390,000 shares, an increase of 12.3% from the October 31st total of 6,580,000 shares. Based on an average daily trading volume, of 3,720,000 shares, the days-to-cover ratio is currently 2.0 days. View Aclaris Therapeutics' Short Interest. When is Aclaris Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our ACRS earnings forecast. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its earnings results on Monday, November, 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.07. The biotechnology company earned $9.30 million during the quarter, compared to analysts' expectations of $1.57 million. Aclaris Therapeutics had a negative net margin of 534.83% and a negative trailing twelve-month return on equity of 64.53%. The business's revenue for the quarter was down 51.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share. What ETFs hold Aclaris Therapeutics' stock? ETFs with the largest weight of Aclaris Therapeutics (NASDAQ:ACRS) stock in their portfolio include Invesco NASDAQ Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Neal Walker's approval rating as Aclaris Therapeutics' CEO? 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX). Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Blackstone Inc. (1.78%), Assenagon Asset Management S.A. (0.97%), FMR LLC (0.93%), Charles Schwab Investment Management Inc. (0.65%), Lord Abbett & CO. LLC (0.64%) and HighTower Advisors LLC (0.52%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACRS) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.